Drugs / sirpiglenastat
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07430202 | Oct 2026 → Oct 2030 expected | fibrolamellar hepatocellular carcinoma | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Recruiting | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT06027086 | Feb 2024 → Sep 2028 expected | fibrolamellar hepatocellular carcinoma | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04471415 | Aug 2020 → Mar 2023 | non-small cell lung carcinoma | Dracen Pharmaceuticals, Inc. | Terminated | No outcome recorded Stop: Enrollment |
| Phase 21 trial | ||||||
| Phase 2 | NCT07249372 | Jan 2026 → Oct 2027 expected | non-small cell lung carcinoma | NYU Langone Health | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 5
| Date | Issuer | Release |
|---|---|---|
| 2021-06-02 | Dracen Pharmaceuticals, Inc. | Results Dracen Announces DRP-104 (sirpiglenastat) Presentation at ASCO 2021 Virtual Annual Meeting dracenpharma.com ↗
The pharmacokinetic and clinical safety profiles from the dose-escalation portion of this ongoing study are similar to what we observed in our comprehensive preclinical program. |
| 2021-04-12 | Dracen Pharmaceuticals, Inc. | Results Dracen Announces DRP-104 (sirpiglenastat) Presentations at AACR Virtual Annual Meeting dracenpharma.com ↗
Additionally, DRP-104 has demonstrated therapeutic synergy with various immune checkpoint inhibitors, including anti-PD-1/PD-L1, anti-CTLA-4 and anti-TIGIT. |
| 2020-10-28 | Dracen Pharmaceuticals, Inc. | Regulatory Dracen Pharmaceutical’s DRP-104 Granted U.S. FDA Fast Track Designation for the treatment of Non-Small Cell Lung Cancer dracenpharma.com ↗ |
| 2020-07-07 | Dracen Pharmaceuticals, Inc. | Results Dracen announces two DRP-104 presentations at AACR dracenpharma.com ↗
Additionally, DRP-104 has demonstrated potent and broad antitumor activity in both murine and patient derived lung adenocarcinoma and squamous tumor models with KEAP1 mutations. |
| 2019-11-08 | Dracen Pharmaceuticals, Inc. | Results Dracen Pharmaceuticals announces DRP-104 presentations at the 2019 Society of Immunotherapy of Cancer (SITC) Meeting dracenpharma.com ↗
Additionally, our preclinical data demonstrate that DRP-104 combines well with immune checkpoint inhibitors leading to significant improvement in survival. |
All press releases naming this drug 7 releases
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | sirpiglenastat | “In addition, we observed a profound decrease in tumor growth in several in vivo models using sirpiglenastat (DRP-104), a pro-drug version of DON that was designed to circumvent...” PMID 37814010 ↗ Oct 2023 |
| Known as | DRP-104 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07430202 ↗ |
| Action | Inhibit | “DRP-104, a Glutamine Antagonist” NCT04471415 ↗ |
| Modality | Small molecule | — CHEMBL4650367 ↗ |
| Route | Intravenous | “DRP-104 administered intravenously over 1 hour” NCT04471415 ↗ |